Related Experiment Videos
Supraventricular tachycardia in the neonate and infant
Moak1
1Children's National Medical Center, Department of Cardiology, George Washington University School of Medicine, 111 Michigan Avenue, NW 20010, Washington, DC, USA
Insights
Supraventricular tachycardia (SVT) is common in infants. Management includes acute interventions and chronic therapies, with radiofrequency ablation generally avoided in this age group due to higher complication rates.
Area of Science:
- Pediatrics
- Cardiology
- Neonatology
Background:
- Supraventricular tachycardia (SVT) is the most frequent sustained arrhythmia in neonates and infants.
- While predisposing factors are present in only 15% of cases, SVT presentation can be subtle, including pallor, cyanosis, and feeding difficulties.
- Congestive heart failure occurs in 35% of infants under 4 months with SVT.
Purpose of the Study:
- To review the epidemiology, presentation, and management of supraventricular tachycardia in neonates and infants.
- To discuss age-related differences in SVT mechanisms and treatment options.
Main Methods:
- Literature review of supraventricular tachycardia in the neonatal and infant population.
- Analysis of SVT mechanisms, clinical presentation, and therapeutic strategies.
Main Results:
- In infants under one year, AV reciprocating tachycardia (80%) is the predominant SVT mechanism, followed by atrial tachycardia (15%) and AV nodal re-entry tachycardia (5%).
- Acute management options include the diving reflex, intravenous adenosine, and transesophageal pacing; intravenous verapamil should be avoided.
- Chronic therapies like digoxin and beta-blockers are effective; radiofrequency ablation is associated with increased complications in this age group.
Conclusions:
- Supraventricular tachycardia in infants requires prompt recognition and appropriate management tailored to the specific mechanism and patient age.
- While chronic medical therapies are effective, radiofrequency ablation should be used cautiously in neonates and infants.
- Further data on untreated SVT recurrence rates are needed.
Abstract:
Supraventricular tachycardia (SVT) is the most common sustained arrhythmia to present in the neonatal and infancy age group. Predisposing factors (congenital heart disease, drug administration, illness and fever) occur only in 15% of infants. The presentation of SVT in the neonate is frequently subtle, and may include pallor, cyanosis, restlessness, irritability, feeding difficulty, tachypnea, diaphoresis and grunting. Congestive heart failure is more common in infants under 4 months of age (35% incidence). Age-related differences in the distribution of SVT mechanisms occur in different age groups. In infants under 1 year of age, the mechanisms underlying SVT are atrial tachycardia (15%), AV nodal re-entry tachycardia (5%), and AV reciprocating tachycardia (80%). Options for acute management include: use of the diving reflex, intravenous adenosine, transesophageal pacing, and cardioversion. Intravenous administration of verapamil should be avoided. Data regarding freedom from recurrence of untreated SVT in the first year of life are limited, and may be in the range of 25-60%. Chronic therapy with digoxin, beta-blockers, flecainide, sotalol and amiodarone has proved effective in controlling recurrent episodes of SVT. Radiofrequency ablation can be employed successfully in medically refractory cases, but should be avoided in this age group (increased complication rate).